Open AccessExploring cancer in LRRK 2 mutation carriers and idiopathic Parkinson's disease
Author(s) -
Warø Bjørg Johanne,
Aasly Jan O.
Publication year - 2018
Publication title -
brain and behavior
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.915
H-Index - 41
ISSN - 2162-3279
DOI - 10.1002/brb3.858
Subject(s) - medicine , breast cancer , cancer , disease , oncology , mutation , brca mutation , genetics , biology , gene
Objectives To compare the risk of non‐skin cancer in LRRK 2 mutation carriers and individuals with idiopathic Parkinson's disease ( iPD ), explore the age at which LRRK 2 mutation carriers have cancer compared to iPD subjects, and clarify whether certain cancers are more closely associated with the LRRK 2 mutation than iPD . Materials and Methods Demographic data and cancer outcomes from 830 iPD patients and 103 LRRK 2 mutation carriers (27 with PD ) were retrospectively collected. Oncologic data were obtained from the Cancer Registry of Norway and included cancer type and age at cancer. All study participants were of Norwegian ethnicity. Results LRRK 2 mutation carriers have increased risk of non‐skin cancer compared with iPD subjects ( OR 2.09; 95% CI 1.16–3.77; p = .015). A significant association was found between the mutation and breast cancer in women ( OR 4.58; 95% CI 1.45–14.51; p = .010). No other associations between harboring a LRRK 2 mutation and specific cancer types were uncovered. Conclusion LRRK 2 mutation carriers have an increased risk of non‐skin cancer compared with iPD subjects, which was mainly driven by the association between harboring the mutation and breast cancer in women. The increased risk is likely independent of ethnicity.